Literature DB >> 12486496

LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes.

A M Wägner1, O Jorba, M Rigla, E Alonso, J Ordóñez-Llanos, A Pérez.   

Abstract

LDL phenotype B is a component of diabetic dyslipidaemia, but its diagnosis is cumbersome. Our aim was to find easily available markers of phenotype B in a group of type 2 diabetic subjects. We studied 123 type 2 diabetic patients (67.5% male, aged 59.3+/-10.1 years, mean HbA1c 7.4%). Clinical features and fasting total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol (LDLc, using Friedewald's equation and an alternative formula), apolipoprotein B (apoB), lipoprotein (a) and LDL particle size (on gradient polyacrylamide gel electrophoresis) were assessed. Patients with phenotypes A (predominant LDL size > or =25.5 nm) and B (<25.5 nm) were compared, and regression analysis was performed to find the best markers of LDL particle. Cut-off points were obtained and evaluated as predictors of phenotype B (kappa index). Patients with phenotype B (36%) showed higher total cholesterol, triglyceride and apolipoprotein B, and lower HDL cholesterol and LDLc/apoB ratio. Triglyceride was the best predictor of LDL particle size (r=-0.632, p<0.01), but an LDLc/apoB ratio below 1.297 mmol/g detected phenotype B best (sensitivity 65.9%, specificity 92.4%, kappa=0.611). Although triglyceride concentration is the best predictor of LDL size in type 2 diabetes, LDLcholesterol/apolipoproteinB ratio is the best tool to detect phenotype B.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12486496     DOI: 10.1007/s005920200037

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  15 in total

Review 1.  Clinical significance of the physicochemical properties of LDL in type 2 diabetes.

Authors:  P G Scheffer; T Teerlink; R J Heine
Journal:  Diabetologia       Date:  2005-04-14       Impact factor: 10.122

2.  Measured Versus Calculated Small Dense LDL-Cholesterol and Cardiometabolic Traits in a South African Population.

Authors:  M Masoud; A P Kengne; R T Erasmus; G M Hon; M Macharia; T E Matsha
Journal:  Indian J Clin Biochem       Date:  2018-03-22

3.  The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.

Authors: 
Journal:  Am Heart J       Date:  2011-02-02       Impact factor: 4.749

4.  Differences in metabolomic and transcriptomic profiles between responders and non-responders to an n-3 polyunsaturated fatty acids (PUFAs) supplementation.

Authors:  Iwona Rudkowska; Ann-Marie Paradis; Elisabeth Thifault; Pierre Julien; Olivier Barbier; Patrick Couture; Simone Lemieux; Marie-Claude Vohl
Journal:  Genes Nutr       Date:  2012-12-19       Impact factor: 5.523

5.  Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particles.

Authors:  Vasilis Tsimihodimos; Irene Gazi; Christina Kostara; Alexandros D Tselepis; Moses Elisaf
Journal:  Lipids       Date:  2007-04-11       Impact factor: 1.880

6.  The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison.

Authors:  Henry S Kahn
Journal:  BMC Cardiovasc Disord       Date:  2005-09-08       Impact factor: 2.298

7.  The apolipoprotein B/apolipoprotein A-I ratio as a potential marker of plasma atherogenicity.

Authors:  Anastasiya M Kaneva; Natalya N Potolitsyna; Evgeny R Bojko; Jon Ø Odland
Journal:  Dis Markers       Date:  2015-03-23       Impact factor: 3.434

8.  Moderate carbohydrate, moderate protein weight loss diet reduces cardiovascular disease risk compared to high carbohydrate, low protein diet in obese adults: A randomized clinical trial.

Authors:  Denise A Walker Lasker; Ellen M Evans; Donald K Layman
Journal:  Nutr Metab (Lond)       Date:  2008-11-07       Impact factor: 4.169

9.  Atherogenic dyslipidemia in children: evaluation of clinical, biochemical and genetic aspects.

Authors:  Anna Montali; Gessica Truglio; Francesco Martino; Fabrizio Ceci; Giampiero Ferraguti; Ester Ciociola; Marianna Maranghi; Francesco Gianfagna; Licia Iacoviello; Roberto Strom; Marco Lucarelli; Marcello Arca
Journal:  PLoS One       Date:  2015-04-21       Impact factor: 3.752

10.  The association between the apolipoprotein A1/ high density lipoprotein -cholesterol and diabetes in Taiwan - a cross-sectional study.

Authors:  Zhi-Hong Jian; Chia-Chi Lung; Pei-Chieh Ko; Yi-Hua Sun; Jing-Yang Huang; Chien-Chang Ho; Chia-Yo Ho; Yi-Chen Chiang; Chien-Jen Chen; Yung-Po Liaw
Journal:  BMC Endocr Disord       Date:  2013-10-07       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.